CHIMERIX INC (CMRX) Stock News
NASDAQ:CMRX - Nasdaq - US16934W1062 - Common Stock
CMRX Latest News and Analysis
Chimerix to Speak Today at The White House Cancer Moonshot Forum
Chief Scientific Officer, Joshua E. Allen, Ph.D. to Highlight Cancer Moonshot’s Impact on Brain Cancer and Rare Pediatric Disease Drug Development
Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma
Secures Access of Up To $30 Million to Support Potential Launch Through Silicon Valley Bank Credit Facility
Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma
Secures Access of Up To $30 Million to Support Potential Launch Through Silicon Valley Bank Credit Facility...
Why Is Cancer-Focused Chimerix Stock Trading Higher On Tuesday?
On Monday, Chimerix (NASDAQ:CMRX) announced that, following extensive dialogue with the FDA, the company plans to submit a complete New Drug Application (NDA) seeking accelerated approval for dordaviprone for recurrent H3 K27M-mutant diffuse glioma in the U.S. before year-end. A glioma is a tumor that originates in the glial cells of the brain or spinal cord and is the most common primary brain tumor. Chimerix stock is trading higher on a strong session volume of 4.31 million, compared to an ave
Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End
Potential Approval in Q3 2025 in Recurrent H3 K27M-Mutant Diffuse Glioma Submission Plan Follows Productive and Collaborative Pre-NDA Interactions with...
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on December 2, 2024, the Compensation Committee of...
Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO Meeting
DURHAM, N.C., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that...
Chimerix Reports Third Quarter 2024 Financial Results and Provides Operational Update
Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024
Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024
DURHAM, N.C., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that...
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on October 16, 2024, the Compensation Committee of...
Chimerix to Present at H.C. Wainwright 26th Annual Global Investment Conference
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on August 20, 2024, the Compensation Committee of Chimerix’s...
CMRX Stock Earnings: Chimerix Meets EPS, Beats Revenue for Q2 2024
CMRX stock results show that Chimerix met analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
CMRX Stock Earnings: Chimerix Meets EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Chimerix (NASDAQ:CMRX) just reported results for the second quarter of 2024.Chi...
Chimerix Reports Second Quarter 2024 Financial Results and Provides Operational Update
Chimerix Reports Second Quarter 2024 Financial Results and Provides Operational Update
– Phase 3 ACTION Study On-Track; First Interim Overall Survival Data Expected Third Quarter 2025 – – ONC206 Phase 1 PK and Safety Data Demonstrate...
Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market
Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market
EQNX::TICKER_START (NYSE:NNVC),(NASDAQ:BCRX),(NASDAQ:VERU),(NASDAQ:CMRX),(NASDAQ:SIGA) EQNX::TICKER_END
Chimerix to Report Second Quarter 2024 Financial Results and Provide an Operational Update on August 13, 2024
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C., July 05, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on July 1, 2024, the Compensation Committee of Chimerix’s...
Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference
Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference
DURHAM, N.C., May 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that...
CMRX Stock Earnings: Chimerix Misses EPS for Q1 2024
CMRX stock results show that Chimerix missed analyst estimates for earnings per share the first quarter of 2024.
Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update
Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update
– Dordaviprone (ONC201) ACTION Study Progressing; Reiterates Expectations for Interim Overall Survival (OS) Data in 2025 and Final OS Data in 2026 – – No...
Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024
DURHAM, N.C., April 24, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that...